FDA sends notice to Congress on LDTs.
The U.S. Food and Drug Administration (FDA) has notified Congress that it intends to issue draft guidance to propose a risk-based, phased-in framework for oversight of laboratory developed tests (LDTs) and, in a strategic move, has provided the anticipated details of the LDT guidance in the notification.
The notification sent on July 31 was required by the Food and Drug Administration Safety and Innovation Act, which requires notification to Congress at least 60 days prior to the issuance of draft or final guidance. Accordingly, the highly politicized environment surrounding changes to the regulation of LDTs can be expected to continue during the 60-day waiting period as industry, academia, and other stakeholders react to the proposed framework.
FDA’s risk-based approach will rely on the existing medical device classification system (Class I, II, or III) to evaluate the risk of a category of LDTs and, informed by the expressed interest in participating in the discussion of the classification process, will use expert advisory panels to help classify devices not previously classified by FDA. FDA intends to issue draft guidance to describe what it considers generally to be Class I, II, or III within 24 months of finalizing the LDT guidance. FDA anticipates that it will phase in enforcement of regulatory requirements for LDTs over the next 10 years. The phased-in enforcement for the different device categories is summarized in the following table.
Click here to view table.
FDA’s notification on the LDT guidance can be accessed here. Additional analyses of the impact of the new regulatory framework for LDTs, FDA’s guidance on in vitro companion diagnostics, and FDA’s actions focusing on personalized medicine will be forthcoming from Morgan Lewis.
On September 26, 2014, we will sponsor a session to discuss the potential impacts on changes to the regulation of LDTs at the BIO IP & Diagnostics Symposium at the Hilton Alexandria Old Town Hotel in Virginia. For more information, see here.